Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced the grant of 48,731 restricted stock units (RSUs) to 26 newly hired non-executive employees. The compensation committee approved these awards under the Ultragenyx Employment Inducement Plan, effective June 16, 2025. The RSUs will vest over a four-year period, with 25% of shares vesting annually on each grant date anniversary. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement for new hires. Ultragenyx, which focuses on developing and commercializing therapies for rare and ultra-rare diseases, uses these equity awards to attract and retain talent.
Ultragenyx Pharmaceutical (NASDAQ: RARE) ha annunciato l'assegnazione di 48.731 unit脿 azionarie vincolate (RSU) a 26 nuovi dipendenti non esecutivi. Il comitato per la remunerazione ha approvato questi premi nell'ambito del Piano di Incentivazione all'Assunzione di Ultragenyx, con effetto dal 16 giugno 2025. Le RSU matureranno in un periodo di quattro anni, con il 25% delle azioni che matureranno ogni anno nell'anniversario della data di assegnazione. Questa assegnazione 猫 stata effettuata in conformit脿 alla Regola di Quotazione Nasdaq 5635(c)(4) come incentivo all'assunzione per i nuovi dipendenti. Ultragenyx, che si concentra sullo sviluppo e la commercializzazione di terapie per malattie rare e ultra-rare, utilizza questi premi azionari per attrarre e trattenere talenti.
Ultragenyx Pharmaceutical (NASDAQ: RARE) ha anunciado la concesi贸n de 48,731 unidades restringidas de acciones (RSU) a 26 empleados no ejecutivos reci茅n contratados. El comit茅 de compensaci贸n aprob贸 estas adjudicaciones bajo el Plan de Incentivos por Empleo de Ultragenyx, vigente a partir del 16 de junio de 2025. Las RSU se consolidar谩n durante un per铆odo de cuatro a帽os, con un 25% de las acciones consolid谩ndose anualmente en cada aniversario de la fecha de concesi贸n. Esta concesi贸n se realiz贸 de acuerdo con la Norma de Cotizaci贸n de Nasdaq 5635(c)(4) como un incentivo de empleo para nuevas contrataciones. Ultragenyx, que se enfoca en desarrollar y comercializar terapias para enfermedades raras y ultra-raras, utiliza estas concesiones de acciones para atraer y retener talento.
Ultragenyx Pharmaceutical (NASDAQ : RARE) a annonc茅 l'attribution de 48 731 unit茅s d'actions restreintes (RSU) 脿 26 nouveaux employ茅s non cadres. Le comit茅 de r茅mun茅ration a approuv茅 ces attributions dans le cadre du Plan d'Incitation 脿 l'Emploi d'Ultragenyx, en vigueur 脿 partir du 16 juin 2025. Les RSU seront acquises sur une p茅riode de quatre ans, avec 25 % des actions acquises chaque ann茅e 脿 la date anniversaire de l'attribution. Cette attribution a 茅t茅 r茅alis茅e conform茅ment 脿 la r猫gle de cotation Nasdaq 5635(c)(4) en tant qu'incitation 脿 l'emploi pour les nouvelles recrues. Ultragenyx, qui se concentre sur le d茅veloppement et la commercialisation de th茅rapies pour les maladies rares et ultra-rares, utilise ces attributions d'actions pour attirer et retenir les talents.
Ultragenyx Pharmaceutical (NASDAQ: RARE) hat die Gew盲hrung von 48.731 Restricted Stock Units (RSUs) an 26 neu eingestellte nicht-exekutive Mitarbeiter bekannt gegeben. Der Verg眉tungsausschuss genehmigte diese Zuweisungen im Rahmen des Ultragenyx Employment Inducement Plan, der ab dem 16. Juni 2025 wirksam ist. Die RSUs werden 眉ber einen Zeitraum von vier Jahren vesten, wobei jeweils 25 % der Aktien j盲hrlich am Jahrestag der Gew盲hrungsdatum vesten. Diese Gew盲hrung erfolgte gem盲脽 der Nasdaq-Listing-Regel 5635(c)(4) als Besch盲ftigungsanreiz f眉r Neueinstellungen. Ultragenyx, das sich auf die Entwicklung und Vermarktung von Therapien f眉r seltene und ultra-seltene Krankheiten spezialisiert hat, nutzt diese Aktienzuteilungen, um Talente anzuziehen und zu binden.
Positive
None.
Negative
None.
NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the company鈥檚 common stock to 26 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company鈥檚 board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx鈥檚 strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: .
Contact Ultragenyx Investors & Media Joshua Higa (415) 475-6370
FAQ
How many restricted stock units did Ultragenyx (RARE) grant to new employees in June 2025?
Ultragenyx granted 48,731 restricted stock units to 26 newly hired non-executive employees.
What is the vesting schedule for Ultragenyx's June 2025 RSU grants?
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the June 16, 2025 grant date.
Under which plan were the Ultragenyx (RARE) RSUs granted in June 2025?
The RSUs were granted under the Ultragenyx Employment Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
What is the purpose of Ultragenyx's RSU grants announced in June 2025?
The RSUs were granted as an inducement material to attract new employees entering into employment with Ultragenyx.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
